Pharma: Other News To Note
• Sosei Group Corp., of Tokyo, and Novartis AG, of Basel, Switzerland, said an application has been submitted for the registration of QVA149, an investigational fixed-dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease in Japan.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST